Abelacimab, a “Game Changer” for High-Risk Patients With AFib: …
6 days ago · Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Study reveals abelacimab’s potential to improve anticoagulation …
5 days ago · Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, …
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
6 days ago · Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral …
Data Published Today in the New England Journal of Medicine ...
Jan 22, 2025 · Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also …
Abelacimab for Prevention of Venous Thromboembolism
Jul 19, 2021 · Abelacimab (MAA868) is a fully human monoclonal antibody that binds to the catalytic domain of factor XI and locks it in the zymogen (inactive precursor) conformation, …
New anti-clotting medication reduces bleeding among people …
Nov 12, 2023 · Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while …
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 ...
Aug 15, 2024 · In the ASTER trial, Anthos’ novel dual-acting Factor XI monoclonal antibody, abelacimab, is being compared to apixaban, the leading Factor Xa inhibitor, to assess their …
Abelacimab: A leap forward in anticoagulation with FXI and FXIa ...
Jan 1, 2024 · Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis. This review provides a comprehensive …
Abelacimab for Prevention of Venous Thromboembolism
Nov 3, 2021 · The protocol allowed the inclusion of patients with a body weight of up to 130 kg and appears to have stipulated a standard dose of enoxaparin at 40 mg administered …
Abelacimab significantly reduces bleeding risk in atrial fibrillation ...
Nov 13, 2023 · An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to …
- Some results have been removed